TriSalus Life Sciences与OrbiMed获得约5000万美元的债务融资

2024-05-01 16:06

TriSalus Life Sciences (NASDAQ:TLSI) on Tuesday announced the closing of a debt financing facility for up to $50 million with OrbiMed, a healthcare investment firm.
The capital is expected to provide financial flexibility to support the execution of strategic expansion plans and fuel continued growth.
Under the terms of the credit agreement, the company borrowed $25 million at closing.
In addition, an aggregate of up to an additional $25 million is available in two tranches at the company’s option, based on the achievement of certain revenue thresholds.
The agreement has a five-year term that matures in April 2029, and in connection with the funding of the closing amount, the company also issued OrbiMed a warrant to purchase 130,805 shares of the company’s common stock, with an exercise price of $9.5562.
Source: Press Release

More on TriSalus Life Sciences